130 related articles for article (PubMed ID: 36472350)
21. [Comparison of efficacy and safety of insulin aspart injection Rishulin and NovoRapid for treatment of diabetes: a multicenter, randomized, open-labeled, controlled trial].
Jia WP; Bao YQ; Miao H; Tu P; Liu Y; Yang T; Wang WB; Shi BY; Liu M; Hua WJ; Hou NN; Zhang Q; Hu L; Pang SG; Liu JD; Wang GX
Zhonghua Nei Ke Za Zhi; 2021 Dec; 60(12):1148-1156. PubMed ID: 34856687
[No Abstract] [Full Text] [Related]
22. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.
Home PD; Lindholm A; Riis A;
Diabet Med; 2000 Nov; 17(11):762-70. PubMed ID: 11131100
[TBL] [Abstract][Full Text] [Related]
23. A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes.
Kapitza C; Nosek L; Schmider W; Teichert L; Mukherjee B; Nowotny I
Diabetes Obes Metab; 2021 Mar; 23(3):674-681. PubMed ID: 33236518
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog
Blevins TC; Raiter Y; Sun B; Donnelly C; Shapiro R; Chullikana A; Rao A; Vashishta L; Ranganna G; Barve A
BioDrugs; 2022 Nov; 36(6):761-772. PubMed ID: 36114990
[TBL] [Abstract][Full Text] [Related]
25. Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes.
Bowering K; Harvey J; Kolaczynski JW; Snyder JW; Bode BW
Diabet Med; 2019 Jun; 36(6):771-775. PubMed ID: 30466191
[TBL] [Abstract][Full Text] [Related]
26. [Biphasic insulin aspart (NovoMix 50)].
Radermecker RP; Scheen AJ
Rev Med Liege; 2008 Nov; 63(11):688-92. PubMed ID: 19112996
[TBL] [Abstract][Full Text] [Related]
27. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.
Basu A; Pieber TR; Hansen AK; Sach-Friedl S; Erichsen L; Basu R; Haahr H
Diabetes Obes Metab; 2018 Jul; 20(7):1615-1622. PubMed ID: 29493118
[TBL] [Abstract][Full Text] [Related]
28. Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart.
Pieber TR; Svehlikova E; Brunner M; Halberg IB; Due Thomsen KM; Haahr H
Diabetes Obes Metab; 2019 Sep; 21(9):2068-2075. PubMed ID: 31069935
[TBL] [Abstract][Full Text] [Related]
29. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers.
Kaku K; Matsuda M; Urae A; Irie S
Diabetes Res Clin Pract; 2000 Aug; 49(2-3):119-26. PubMed ID: 10963823
[TBL] [Abstract][Full Text] [Related]
31. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
[TBL] [Abstract][Full Text] [Related]
32. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes.
Lindholm A; McEwen J; Riis AP
Diabetes Care; 1999 May; 22(5):801-5. PubMed ID: 10332685
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes.
DeVries JH; Lindholm A; Jacobsen JL; Heine RJ; Home PD;
Diabet Med; 2003 Apr; 20(4):312-8. PubMed ID: 12675646
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections.
Cemeroglu AP; Kleis L; Wood A; Parkes C; Wood MA; Davis AT
Endocr Pract; 2013; 19(4):614-9. PubMed ID: 23425652
[TBL] [Abstract][Full Text] [Related]
35. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.
Haahr H; Heise T
Clin Pharmacokinet; 2020 Feb; 59(2):155-172. PubMed ID: 31667789
[TBL] [Abstract][Full Text] [Related]
36. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
[TBL] [Abstract][Full Text] [Related]
38. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
Lane WS; Favaro E; Rathor N; Jang HC; Kjærsgaard MIS; Oviedo A; Rose L; Senior P; Sesti G; Soto Gonzalez A; Franek E
Diabetes Care; 2020 Aug; 43(8):1710-1716. PubMed ID: 32209647
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.
Bode BW; Strange P
Diabetes Care; 2001 Jan; 24(1):69-72. PubMed ID: 11194244
[TBL] [Abstract][Full Text] [Related]
40. Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.
Haahr H; Pieber TR; Mathieu C; Gondolf T; Shiramoto M; Erichsen L; Heise T
Clin Pharmacokinet; 2019 May; 58(5):639-649. PubMed ID: 30402720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
